Samsung Bioepis Appoints Kim Kyung-ah as New CEO After 13 Years

Samsung Bioepis announced a leadership change for the first time in 13 years.

On the 27th, the company announced that Kim Kyung-ah, Executive Vice President and Head of Development, has been promoted to President and CEO.

The new CEO, Kim Kyung-ah, is a biosimilar development expert with a Bachelor’s and Master’s degree in Pharmacy from Seoul National University and a Ph.D. in Toxicology from Johns Hopkins University in the United States. She joined Samsung Electronics' Advanced Institute of Technology in 2010 as a senior researcher in biopharmaceutical development and later joined Samsung Bioepis in 2015. Kim has played a pivotal role across the company’s operations, including biosimilar development, processes, quality, and regulatory affairs.

With this promotion, Kim becomes the first female professional CEO in Samsung Group’s history. The company explained that her appointment is expected to provide a vision for growth to other female talent, encourage bold challenges, and serve as a role model for women within Samsung Bioepis, bringing new energy to the organization. Notably, over half of Samsung Bioepis’ workforce is female.

Samsung Bioepis stated, “CEO Kim Kyung-ah will continue to drive innovation and growth for Samsung Bioepis with her expertise in biopharmaceuticals and integrative leadership.”

Ko Han-sung, who has led Samsung Bioepis since its founding in 2012, will transition to Samsung Electronics as President and Head of the Future Business Planning Division.